Arginine Vasopressin in Advanced Vasodilatory Shock
- 13 May 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (18), 2313-2319
- https://doi.org/10.1161/01.cir.0000066692.71008.bb
Abstract
Background— Vasodilatory shock is a potentially lethal complication of severe disease in critically ill patients. Currently, catecholamines are the most widely used vasopressor agents to support blood pressure, but loss of catecholamine pressor effects is a well-known clinical dilemma. Arginine vasopressin (AVP) has recently been shown to be a potent vasopressor agent to stabilize cardiocirculatory function even in patients with catecholamine-resistant vasodilatory shock. Methods and Results— Forty-eight patients with catecholamine-resistant vasodilatory shock were prospectively randomized to receive a combined infusion of AVP and norepinephrine (NE) or NE infusion alone. In AVP patients, AVP was infused at a constant rate of 4 U/h. Hemodynamic, acid/base, single-organ, and tonometrically derived gastric variables were reported before the study and 1, 12, 24, and 48 hours after study entry. For statistical analysis, a mixed-effects model was used. AVP patients had significantly lower heart rate, NE requirements, and incidence of new-onset tachyarrhythmias than NE patients. Mean arterial pressure, cardiac index, stroke volume index, and left ventricular stroke work index were significantly higher in AVP patients. NE patients developed significantly more new-onset tachyarrhythmias than AVP patients (54.3% versus 8.3%). Gastrointestinal perfusion as assessed by gastric tonometry was better preserved in AVP-treated patients. Total bilirubin concentrations were significantly higher in AVP patients. Conclusions— The combined infusion of AVP and NE proved to be superior to infusion of NE alone in the treatment of cardiocirculatory failure in catecholamine-resistant vasodilatory shock.This publication has 23 references indexed in Scilit:
- Depletion of neurohypophyseal content of vasopressin in septic shock*Critical Care Medicine, 2002
- The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective AnalysisAnesthesia & Analgesia, 2001
- Treatment of Intraoperative Refractory Hypotension with Terlipressin in Patients Chronically Treated with an Antagonist of the Renin-Angiotensin SystemAnesthesia & Analgesia, 1999
- The Effects of Vasopressin on Endotoxin-Induced Attenuation of Contractile Responses in Human Gastroepiploic Arteries In VitroAnesthesia & Analgesia, 1999
- On the Inotropic Actions of Arginine Vasopressin in Ventricular Muscle of the Guinea Pig Heart.The Japanese Journal of Pharmacology, 1999
- Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agentThe Journal of Thoracic and Cardiovascular Surgery, 1998
- Vasopressin for the Treatment of Refractory Hypotension After Cardiopulmonary BypassAnesthesia & Analgesia, 1998
- Arginine vasopressin inhibits interleukin-1β-stimulated nitric oxide and cyclic guanosine monophosphate production via the V1 receptor in cultured rat vascular smooth muscle cellsJournal of Hypertension, 1997
- Comparison of Peptide and Nonpeptide Receptor-Mediated Responses in Rat Tail ArteryJournal of Cardiovascular Pharmacology, 1992
- American College of Chest Physicians/Society of Critical Care Medicine Consensus ConferenceCritical Care Medicine, 1992